Inactive compounds

Next, the technique described above (our method) was applied to the subclasses of inactive and intermediate compounds. This time 25 active compounds and 35 inactive compounds (fi om the remaining 68) were correctly classified by the same method, namely, KSOM. 

A/ -Monosubstitution may result in greater activity, and will increase activity with a number of heterocycles A/ -disubstitution in general leads to inactive compounds. 

The presence of a small substituent capable of forming hydrogen bonds in the 4 -position. Isosteric groups such as NH2 reduce activity, whereas any other group that cannot be converted metabohcaHy to a 4 -OH group results in inactive compounds. 

Similar conformational analyses were performed for inactive compounds, and inactive compounds in pharmacophoric conformations were superimposed with the active compounds to determine steric limitations in the active site. Where appropriate, the geometry of each inactive molecule was obtained by modifying the chemical strucmre of the relevant active analogs followed by the energy minimization of the resulting structure. 

The essential feature of the AAA is a comparison of active and inactive molecules. A commonly accepted hypothesis to explain the lack of activity of inactive molecules that possess the pharmacophoric conformation is that their molecular volume, when presenting the pharmacophore, exceeds the receptor excluded volume. This additional volume apparently is filled by the receptor and is unavailable for ligand binding this volume is termed the receptor essential volume [3]. Following this approach, the density maps for each of the inactive compounds (in their pharm conformations superimposed with that of active compounds) were constructed the difference between the combined inactive compound density maps and the receptor excluded volume represents the receptor essential volume. These receptor-mapping techniques supplied detailed topographical data that allowed a steric model of the D[ receptor site to be proposed. 

The elimination of drag s from the body is called excretion. After the liver renders drag s inactive, the kidney excretes the inactive compounds from the body. Also, some dragp are excreted unchanged by the kidney without liver involvement. Fhtients with kidney disease may require a dosage reduction and careful monitoring of... 

Epinephrine is an inherently unstable chemical in aqueous solution, even at a low pH and in the presence of an antioxidant such as sodium metabisulfite, up to 1 mg/ ml. With the passage of time, the epinephrine dose gradually decreases due to degradation into inactive compounds. If the expiry date has passed, the epinephrine dose correlates inversely with the number of months or years past that date, and will likely be lower than the dose stated on the label even if the solution appears clear and colorless. Nevertheless, if this is the only source of epinephrine available for injection, it should be used in preference to not administering epinephrine at all [32]. 

For inactive compounds, there will be a lower bound on the activity Xc . This limit corresponds to either the point at which the measurements were halted because of lack of interest or the detection limit of the assay. For compounds with X-ray data, there will be an experimentally verified conformation yc... 

Because we only have a lower bound on the binding free energy of inactive compounds, we expect ... 

Finally, derivatives of the endogenous compound 2-octyl- y-bromoacetate (65) have been reported as FAAH inhibitors [79]. In a limited SAR study, it was found that replacement of the bromine with a chlorine atom had little effect on affinity. The replacement of the alkyl chain with oleyl-chain mimics resulted in an increase of affinity for FAAH (approximately 5-fold). The removal of the halogen and replacement with either a proton or methyl resulted in inactive compounds. The most potent compound identified in this series was compound (66) with an IC50 value of 0.6/rM [79]. 

In general for the C20 series, maximal activity is achieved with amides of arachidonic acid (1) [81], mead acid (199) [149], and dihomo-y-linoleic acid (200) [150] (see Table 6.18). Decreasing the unsaturation (201), (202), or abolishment of the n-pentyl chain (203) [150] led to less active or inactive compounds. Variable results were seen with longer chains. The C22 4 n-6 analogue (204) is as active as AEA (1) whereas the C22 6 n-3 analogue (205) is less active than the C20 5 n-3 analogue (203) [150]. Replacement of the double bonds with triple bonds (206) resulted in loss of activity [150] (see Table 6.18). Forcing the fatty acid chain into a hairpin conformation by cyclisation (207) also resulted in inactive compounds [151]. 

CXCR2 is a member of the CXC family of chemokine receptors. IL-8 activates this receptor, and an antagonist would potentially be useful for the treatment of inflammatory diseases. Baxter et al. [58] describe the parallel optimization of binding and functional potency, physicochemical properties, ADME properties, and PK. The thiol of the HTS hit was varied with typical replacements (i.e., OH, NH2, SMe, NHAc, etc.), but this only led to inactive compounds. Variation of the substituent at N(2) showed that a benzyl moiety was required (Ph, Me substituents gave inactive compounds). Variation of the C(5) substituent showed that -substituents produced optimal activity. The optimized lead has substantially improved CXCR2 binding and functional activity as well as an excellent PK profile (Scheme 13). 

The antidote of choice for mechlorethamine extravasations is sodium thiosulfate. This agent binds alkylating agents, resulting in neutralization to inactive compounds that are then excreted. Sodium thiosulfate also may be effective for high-concentration cisplatin or dacarbazine extravasations. 

The replacement of the one remaining hydrogen atom in the bridge of (p-ClC6H4)2-CHCFCh gave an inactive compound against the fruit fly, the only insect tested. This is precedented by the known inactivity of (p-ClCeH CClCCh. 

RL Smith. The role of the gut flora in the conversion of inactive compounds to active metabolites. In A Symposium on Mechanisms of Toxicity. WN Aldridge, ed. New York Macmillan, 1971, pp. 228-244. 

Figure 16 Overlay of volume maps of active compounds and inactive compounds. 

In a recent paper by Salimbeni et al. [2], a novel series of such All antagonists has been presented on the basis of a comparative analysis of theoretical distributions of the electrostatic potential (computational model of an All active conformation, it was found that the compound named LR-B/081 [3, 4] (C3oH30N603S), i.e. 2-[(6-butyl-2-methyl-4-oxo-5- 4-[2-(lH-tetrazol-5-yl)phenyl] benzyl -3H-pyrimidin-3-yl)methyl]-3-thiophenecarboxylate (Scheme 1), was one of the most potent in the series, and was selected as a candidate for further studies. 

Inhibitors can be injected into the system in order to kill active species present, for example, by neutralizing the catalyst or by capturing free radicals in a polymerization. For example, the Lewis acid, BF3-complex can be killed using gaseous NH3 since the inactive compound BF3 NH3 is formed, and the reaction stops for lack of active centers. An antioxidant such as hydroquinone can be used to capture peroxide radicals to control reactions involving vinyl-type monomeric substances. 

---